Tanxitumab combined with lenalidomide approved for the treatment of relapsed/refractory diffuse larg

Tencetuximab combined with lenalidomide has been approved in Macau for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Novogene (Shanghai Stock Exchange code: six hundred and eighty-eight thousand four hundred and twenty-eight; Hong Kong Stock Exchange code: nine thousand nine hundred and sixty-nine) announced today that Tencetuximab combined with lenalidomide has been approved in Macau for the treatment of relapsed/refractory diffuse large B-cell lymphoma.